Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: crysball who wrote (961)	7/8/1998 4:39:00 PM
From: Ariella	Read Replies (2) \| Respond to of 1491

Pharmos kindly provided me with the 6/11 Sturza report: He doesn't say anything we don't know, but it was nice to see in print that he believes , based on the mortality rates already published by the company, that HU-211 provides "a meaningful benefit" to the patients who are taking it. He reiterates his STRONG BUY recommendation and the target price of $6/share. Personal to Crys, I was out there bidding at 2 15/32 midday today. Like you, couldn't believe how cheap the stock had gotten. Happy trading all, Ariella